by | Jan 22, 2026 | Diamond, Michael, Fremont, Daved, Hui, Sean, Li, Pengfei
— Published date: 1/14/2026
Value Proposition: Entry receptors that bind directly to TBEV, promoting virus attachment to treat TBEV and other viruses.
Technology Description
Researchers at Washington University in St. Louis have developed LRP8 soluble decoy receptors (minimal domains-Fc fusion …
by | Jan 22, 2026 | Diamond, Michael, Palakurty, Sathvik, Raju, Saravanan, Sariol, Alan
— Published date: 1/14/2026
Value Proposition: Soluble engineered decoy receptor protein that on its own can be used to treat multiple alphavirus types.
Technology Description
Researchers at Washington University in St. Louis have developed a composition of matter that consists of a mutagenized…
by | Jan 13, 2026 | Brestoff Parker, Jonathan, Diamond, Michael, Jia, Wentong
— Published date: 1/14/2026
Value Proposition: Novel target for therapeutic treatment of obesity and related metabolic diseases.
Technology Description
Researchers at Washington University in St. Louis have developed a therapeutic targeting MXRA8 to treat obesity and associated metabolic disea…
by | Sep 17, 2025 | Fremont, Daved, Nelson, Christopher, Teitelbaum, Steven, Warren, Julia
— Published date: 9/18/2025
Value Proposition: Single chain RANK ligand that can selectively inhibit pathological bone loss.
Technology Description
Researchers at Washington University in St. Louis have developed a genetically engineered mutant RANKL protein that prevents bone loss by selective…
by | Jun 3, 2025 | Feldman, Mario, Jana, Biswanath, Pardue, Evan, Sartorio, Mariana
— Published Date: 6/3/2025
Value Proposition: System that employs gut microbe strains engineered with therapeutic enzymes to treat chronic gut conditions.
Technology Description
Researchers at Washington University in St. Louis have developed a hypervesiculating Bacteroides theatiotaomicron (Bt) …